Browsing by Author "Villegas, JA"

Now showing 1 - 1 of 1

GATA-3 is a proto-oncogene in T-cell lymphoproliferative neoplasms
(Springer Nature, 2022) Geng, X; Wang, C; Gao, X; Chowdhury, P; Weiss, J; Villegas, JA; Saed, B; Perera, T; Hu, Y; Reneau, J; Sverdlov, M; Wolfe, A; Brown, N; Harms, P; Bailey, NG; Inamdar K; Hristov, AC; Tejasvi, T; Montes, J; Barrionuevo, C; Taxa-rojas, L; Casavilca-Sambrano, S; de Pádua Covas Lage JLA; Culler HF; Pereira, J; Runge, JS; Qin, T; Tsoi, LC; Hong, HS; Zhang L; Lyssiotis, CA; Ohe, R; Toubai, T; Zevallos-Morales, A; Murga-Zamalloa, C; Wilcox, RA
Neoplasms originating from thymic T-cell progenitors and post-thymic mature T-cell subsets account for a minority of lymphoproliferative neoplasms. These T-cell derived neoplasms, while molecularly and genetically heterogeneous, exploit transcription factors and signaling pathways that are critically important in normal T-cell biology, including those implicated in antigen-, costimulatory-, and cytokine-receptor signaling. The transcription factor GATA-3 regulates the growth and proliferation of both immature and mature T cells and has recently been implicated in T-cell neoplasms, including the most common mature T-cell lymphoma observed in much of the Western world. Here we show that GATA-3 is a proto-oncogene across the spectrum of T-cell neoplasms, including those derived from T-cell progenitors and their mature progeny, and further define the transcriptional programs that are GATA-3 dependent, which include therapeutically targetable gene products. The discovery that p300-dependent acetylation regulates GATA-3 mediated transcription by attenuating DNA binding has novel therapeutic implications. As most patients afflicted with GATA-3 driven T-cell neoplasms will succumb to their disease within a few years of diagnosis, these findings suggest opportunities to improve outcomes for these patients.